Akash Tawari

Analyst

Jefferies

Equibles does not estimate personal net worth.

About Akash Tawari

Akash Tawari is recorded as Analyst at Jefferies. Akash Tawari has spoken on 7 earnings calls across 6 companies, most recently for Cytokinetics Inc on November 4, 2026. Those appearances were for Biomarin Pharmaceutical Inc (BMRN), Cytokinetics Inc (CYTK), Vertex Pharmaceuticals Inc (VRTX), Regeneron Pharmaceuticals, Inc. (REGN), Alkermes plc. (ALKS) and 1 other company. The companies whose calls Akash Tawari spoke on are classified in the Healthcare sector.

Akash Tawari on recent calls

“So, I wonder if you were to comment on, you know, Edgewise is proposing kind of a phase-free design without echo-guided dose adjustments, more of a kind of symptomatic paradigm.”

Analyst — Jefferies, Cytokinetics Q3 2026 Earnings Conference Call · November 4, 2026

“Can you talk a bit more about your decision to file on two-year EGFR data? I know you were going to make a decision. I was anticipating sometime next year. It sounds like you're making the call now.”

Analyst — Jefferies, Vertex Pharmaceuticals Inc Q3 FY2026 Earnings Call · November 2, 2026

“I noticed that your Sanofi collaboration allows you to add another early stage Sanofi asset. Can we revisit, you know, stat six?”

Analyst — Jefferies, Regeneron Pharmaceuticals Q3 2026 Earnings Conference Call · October 30, 2026

“So any lessons from the TRISCRL for their once-nightly low sodium oxybate, do you feel like you'd be able to file on PK data? And where do you currently stand with your program?”

Analyst — Jefferies, Q2 2026 Alkermes plc Earnings Conference Call · July 28, 2026

“For DAZO's Phase 3 Sjogren's programs, you're making an interesting bet splitting it up into systemic and symptomatic patients. What kind of drove that decision, and which one of those trials are you more confident will work?”

Analyst — Jefferies, Amgen Q1 2026 Earnings Conference Call · April 30, 2026